Latest MS research update -Combining complementary medicine with traditional treatments - 25 February 2014
The MS Trust runs a weekly search for interesting and relevant research articles relating to multiple sclerosis using Medline, a specialised search engine for medical journals. The original abstracts to each of the articles can be accessed via the links provided.
For further information on any topic please contact the information team at firstname.lastname@example.org.
This week's highlighted research...
Research by topic areas...
- Symptoms and symptom management
- MS relapses
- Disease modifying treatments
- Drugs in development
- Other treatments
- Assessment tools
- Quality of life
- Causes of MS
- Paediatric MS
- Psychological aspects
- Physical activity
- Stem Cells
Combining complementary medicine with traditional treatments
Complementary and alternative medicine (CAM) refers to those forms of treatment that are not widely in use in conventional medicine. This small study looked at how people with MS viewed the risks of combining CAM and conventional drug treatments (CDT) in the management of their MS.
The researchers found that the 11 participants felt that using CAM and CDT together, was safe and risk-free, as they did not feel ill after using the CAM. It is known that some CAM treatments can interact and interfere with some CDTs, but the study found that the participants had given little thought to the potential risks of doing so and the possible negative interactions that could occur.
The study suggests that more needs to be known about the way people use their body sensations and experience as a measure of safety when using CAM and how this can affect communication with their doctors.
It is known that many people with MS use complementary and alternative medicine (CAM) treatments in the management of their disease. Typically people with MS who use CAM also use conventional drug treatments (CDT). Some CAM treatments can interact and interfere with CDT, but little is known about how users consider such risks. This study aimed to find out about how users view the risk of combining CAM and CDT in the management of their MS.
How this study was carried out
The researchers had surveyed members of the Danish MS Society. Just over half (52%) of the 1,865 people with MS who had responded in the survey had used CAM within the past 12 months and most of these people (90%) had used CAM at the same time as conventional treatments.
11 of the survey respondents were selected for in-depth follow up interviews to explore their views on using CAM and conventional medicine together and the potential risks of doing so. The 11 were selected as they were typical of the survey respondents that used CAM and conventional medicine together. All 11 were women, aged between 31 and 39, with a high level of education.
Each participant took part in an interview that lasted between 35 and 65 minutes and focused on their use of CDT and CAM. The interview questions included: "Would you like to tell me about your life with MS?", "In your experience, what affects the development of your MS?", "Why do you use herbal medicine?" and "What are your experiences of using herbal medicine/ other CAM?".
The answers given during the interviews were examined and general themes and opinions were identified.
What was found
The participants felt that using CAM and CDT together, was safe and risk-free. The participants said they thought CAMs, such as herbal medicine, were 'non-chemical' and 'natural'. They also used their body sensations and experience as an indicator of safety, so if they didn't feel ill after using the CAM they concluded it was safe. The participants had great trust in their CAM practitioner and relied on them to make them aware of any possible problems with the CAM they would use. The participants also expressed problems in talking with their usual medical doctor about CAM. Many felt their doctor didn't know about it or did not want to talk about it. Those doctors that did mention the risks of using CAM together with CDT did not give information that was useful or informative, such as the reasons why something could be a problem.
What does it mean?
The study suggests that people using CAM alongside their conventional treatments have given little thought to the potential risks of doing so and the possible negative interactions that could occur. Those questioned had also not received such advice from either their CAM practitioner or their medical doctor.
The authors conclude that more needs to be known about the way people use their body sensations and experience as a measure of safety when using CAM and how this can affect communication with their doctors.
Skovgaard L, Pedersen IK, Verhoef M.
Use of bodily sensations as a risk assessment tool: exploring people with Multiple Sclerosis' views on risks of negative interactions between herbal medicine and conventional drug therapies.
BMC Complement Altern Med. 2014 Feb 18;14(1):59.
More about complementary and alternative medicine
Complementary and alternative medicine (CAM) refers to those forms of treatment that are not widely in use in conventional medicine. Commonly used therapies include: acupuncture, Chinese medicine, aromatherapy and homoeopathy. CAM is popular with people with MS with studies showing that between a third and a half of people with MS regularly use at least one therapy.
There are a number of CAM therapeutic approaches that are sometimes helpful in the treatment of MS. However as this study shows there is a widespread belief that CAMs must be safe as they are seen as being 'natural', but this may not always be the case. Like conventional medicines CAMs can have side effects and can also interact with conventional therapies. For example St John's wort is taken by many people to treat depression and it has shown to be effective. However it can have serious interactions with other drugs, including other antidepressants, as well as stopping warfarin (a blood thinning drug) and oral contraceptives from working, leading to the risk of blood clots or unwanted pregnancy in people taking these drugs. Preparations of remedies such as St John's wort can also vary in their strength and effect, so it is not possible to be sure how much you are taking as they are not standardised. It is therefore important that people with MS tell their health professionals if they are taking or considering using any CAMs, so any potential interaction or risk can be discussed.
Finding appropriate therapies
As with most subjects there is a great deal of information about CAM on the internet, but much of this is not impartial or reliable. Also, in contrast to conventional medicine, there is not a great deal of published research evidence on the effectiveness or benefits of CAM. If you are interested in trying a particular therapy you should consult a trusted source where possible for information such as NHS Choices or your MS team.
Always check that a practitioner has appropriate qualifications or is registered with an appropriate regulatory organisation. Be aware of the cost of treatment and how long it is likely to last. Therapies can be expensive, so it is sensible to know when to stop if no benefit is being obtained. Not everything works for everybody, so it would be useful to decide in advance how long it would be reasonable to try something out for before concluding if it is working for you or not.
Keep up to date
You can sign up to receive an email alert for the MS Trust research update. The email provides links to this page so that you can see the latest published research in MS. You can read our blog on how we choose research to include in this update.
You can also sign up for our News alerts which cover reports about MS on our news page and in the media.
Open Door, the MS Trust's free quarterly newsletter is available both by post and by email. It contains information on all the publications and support that the MS Trust provides, articles on a wide range of topics written by health professionals and people with MS as well as news about MS and recent research. Sign up for Open Door here or call us on 0800 032 38 39 or 01462 476700
The diagnosis of multiple sclerosis and the various related demyelinating syndromes: A critical review.
J Autoimmun. 2014 Feb 10. pii: S0896-8411(14)00025-0.[Epub ahead of print]
Deangelis TM, Miller A.
Diagnosis of multiple sclerosis.
Handb Clin Neurol. 2014;122:317-42.
Aliaga ES, Barkhof F.
MRI mimics of multiple sclerosis.
Handb Clin Neurol. 2014;122:291-316.
Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation.
Handb Clin Neurol. 2014;122:269-90.
Symptoms and symptom management
Sumowski JF, Leavitt VM.
Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure.
Arch Phys Med Rehabil. 2014 Feb 19. pii: S0003-9993(14)00126-9.[Epub ahead of print]
Viner R, Fiest KM, Bulloch AG, et al.
Point prevalence and correlates of depression in a national community sample with multiple sclerosis.
Gen Hosp Psychiatry. 2014 Jan 13. pii: S0163-8343(14)00003-6.[Epub ahead of print]
Braley TJ, Segal BM, Chervin RD.
Obstructive sleep apnea and fatigue in patients with multiple sclerosis.
J Clin Sleep Med. 2014 Feb 15;10(2):155-62.
Fernández-de-Las-Peñas C, Ortega-Santiago R, Ortíz-Gutiérrez R, et al.
Widespread pressure pain hypersensitivity in patients with multiple sclerosis with and without pain as sign of central sensitization.
Clin J Pain. 2014 Feb 12. [Epub ahead of print]
urological challenge: Voiding dysfunction in multiple sclerosis.
Can Urol Assoc J. 2013 Sep;7(9-10 Suppl 4):S181-S182.
Toosy A, Ciccarelli O, Thompson A.
Symptomatic treatment and management of multiple sclerosis.
Handb Clin Neurol. 2014;122:513-62.
Disease modifying treatments
Butzkueven H, Kappos L, Pellegrini F, et al.
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
J Neurol Neurosurg Psychiatry. 2014 Feb 14.[Epub ahead of print]
Bergvall N, Makin C, Lahoz R, et al.
Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
PLoS One. 2014 Feb 6;9(2):e88472.
Frisullo G, Calabrese M, Tortorella C, et al.
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.
Mult Scler. 2014 Feb 10. [Epub ahead of print]
Derwenskus J, Lublin FD., et al.
Future treatment approaches to multiple sclerosis.
Handb Clin Neurol. 2014;122:563-77.
Immunosuppressive treatments in multiple sclerosis.
andb Clin Neurol. 2014;122:503-11.
O'Connor PW, Oh J.
Disease-modifying agents in multiple sclerosis.
Handb Clin Neurol. 2014;122:465-501.
Alemtuzumab treatment of multiple sclerosis.
Semin Neurol. 2013 Feb;33(1):66-73.
Phillips JT, Fox RJ.
BG-12 in multiple sclerosis.
emin Neurol. 2013 Feb;33(1):56-65.
Oh J, O'Connor PW.
Teriflunomide for the treatment of multiple sclerosis.
Semin Neurol. 2013 Feb;33(1):45-55.
Willis MA, Cohen JA.
Fingolimod therapy for multiple sclerosis.
Semin Neurol. 2013 Feb;33(1):37-44.
Derfuss T, Kuhle J, Lindberg R, et al.
Natalizumab therapy for multiple sclerosis.
Semin Neurol. 2013 Feb;33(1):26-36.
Therapeutic decision making in a new drug era in multiple sclerosis.
Semin Neurol. 2013 Feb;33(1):5-12.
Keegan BM., et al.
Therapeutic decision making in a new drug era in multiple sclerosis.
Semin Neurol. 2013 Feb;33(1):5-12.
Fredrikson S, McLeod E, Henry N, et al.
A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.
J Med Econ. 2013;16(6):756-62.
Lampl C, Nagl S, Arnason B, et al.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
J Neurol. 2013 Jul;260(7):1838-45.
Drugs in development
Vollmer TL, Sorensen PS, Selmaj K, et al.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
J Neurol. 2014 Feb 18. [Epub ahead of print]
Kochs L, Wegener S, Sühnel A, et al.
The use of complementary and alternative medicine in patients with multiple sclerosis: A longitudinal study.
Complement Ther Med. 2014 Feb;22(1):166-72.
Flachenecker P, Henze T, Zettl UK.
Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Eur Neurol. 2014 Feb 12;71(5-6):173-181. [Epub ahead of print]
Glucocorticoid treatment of multiple sclerosis.
Handb Clin Neurol. 2014;122:455-64.
Ristori G, Romano S, Cannoni S, et al.
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS.
Neurology. 2014 Jan 7;82(1):41-8.
Mahajan ST, Frasure HE, Marrie RA.
The prevalence of urinary catheterization in women and men with multiple sclerosis.
J Spinal Cord Med. 2013 Nov;36(6):632-7.
Shaygannejad V, Janghorbani M, Vaezi A, et al.
Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis.
Neurol Res. 2013 Jul;35(6):636-41.
The epidemiology of multiple sclerosis: insights to disease pathogenesis.
Handb Clin Neurol. 2014;122:231-66.
Mackenzie IS, Morant SV, Bloomfield GA, et al.
Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database.
J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):76-84.
Archer C, Morris L, George S.
ssessment and rehabilitation of driver skills: subjective experiences of people with multiple sclerosis and health professionals.
Disabil Rehabil. 2014 Feb 21. [Epub ahead of print]
Tabrizi YM, Mazhari S, Nazari MA, et al.
Abnormalities of motor imagery and relationship with depressive symptoms in mildly disabling relapsing-remitting multiple sclerosis.
J Neurol Phys Ther. 2014 Feb 13. [Epub ahead of print]
Ben Ari Shevil E, Johansson S, Ytterberg C, et al.
How are cognitive impairment, fatigue and signs of depression related to participation in daily life among persons with multiple sclerosis?
Disabil Rehabil. 2014 Feb 14. [Epub ahead of print]
Salminen AL, Kanelisto KJ, Karhula ME.
What components of rehabilitation are helpful from the perspective of individuals with multiple sclerosis?
Disabil Rehabil. 2014 Feb 10. [Epub ahead of print]
Arias DE, Pino EJ, Aqueveque P, et al.
Data collection capabilities of a new non-invasive monitoring system for patients with advanced multiple sclerosis.
AMIA Annu Symp Proc. 2013 Nov 16;2013:61-8. eCollection 2013.
Learmonth YC, Hubbard EA, McAuley E, et al.
Psychometric properties of quality of life and health-related quality of life assessments in people with multiple sclerosis.
Qual Life Res. 2014 Feb 14. [Epub ahead of print]
MRI outcomes in the diagnosis and disease course of multiple sclerosis.
Handb Clin Neurol. 2014;122:405-25.
Clinical outcome measures in multiple sclerosis.
Handb Clin Neurol. 2014;122:393-404.
Quality of life
Galushko M, Golla H, Strupp J, et al.
Unmet needs of patients feeling severely affected by multiple sclerosis in germany: a qualitative study.
J Palliat Med. 2014 Feb 14. [Epub ahead of print]
Causes of MS
Venkatesan A, Johnson RT.
Infections and multiple sclerosis.
Handb Clin Neurol. 2014;122:151-71.
Hedström AK, Hillert J, Olsson T, et al.
Smoking and multiple sclerosis susceptibility.
Eur J Epidemiol. 2013 Nov;28(11):867-74.
Multiple sclerosis in children.
Handb Clin Neurol. 2014;122:427-41.
Genetics of primary progressive multiple sclerosis.
Handb Clin Neurol. 2014;122:211-30.
Multiple sclerosis genetics.
Handb Clin Neurol. 2014;122:193-209.
Rosti-Otajärvi EM, Hämäläinen PI.
Neuropsychological rehabilitation for multiple sclerosis.
Cochrane Database Syst Rev. 2014 Feb 11;2:CD009131. [Epub ahead of print]
Chiaravalloti ND, Moore NB, Nikelshpur OM, et al.
An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial.
Neurology. 2013 Dec 10;81(24):2066-72.
Denommé LT, Mandalfino P, Cinelli ME.
Strategies used by individuals with multiple sclerosis and with mild disability to maintain dynamic stability during a steering task.
Exp Brain Res. 2014 Feb 22. [Epub ahead of print]
Rietberg MB, van Wegen EE, Kollen BJ, et al.
Do patients with multiple sclerosis show different daily physical activity patterns from healthy individuals?
Neurorehabil Neural Repair. 2014 Feb 10. [Epub ahead of print]
Crittendon A, O'Neill D, Widener GL, et al.
Standing data disproves biomechanical mechanism for balance-based torso-weighting.
Arch Phys Med Rehabil. 2014 Jan;95(1):43-9.
Klaren RE, Motl RW, Dlugonski D, et al.
Objectively quantified physical activity in persons with multiple sclerosis.
Arch Phys Med Rehabil. 2013 Dec;94(12):2342-8.
Dalgas U, Stenager E, Lund C, et al.
Neural drive increases following resistance training in patients with multiple sclerosis.
J Neurol. 2013 Jul;260(7):1822-32.
Rossi S, Studer V, Motta C, et al.
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
J Neuroinflammation. 2014 Feb 18;11(1):32. [Epub ahead of print]
Swanton J, Fernando K, Miller D.
Early prognosis of multiple sclerosis.
Handb Clin Neurol. 2014;122:371-91.
Confavreux C, Vukusic S.
The clinical course of multiple sclerosis.
Handb Clin Neurol. 2014;122:343-69.
Kalincik T, Vivek V, Jokubaitis V, et al.
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
Brain. 2013 Dec;136(Pt 12):3609-17.
Burman J, Iacobaeus E, Svenningsson A, et al.
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
J Neurol Neurosurg Psychiatry. 2014 Feb 19.[Epub ahead of print]
Doogan C, Playford ED.
Supporting work for people with multiple sclerosis.
Mult Scler. 2014 Feb 13. [Epub ahead of print]
Marrie RA, Salter A, Tyry T, et al.
Health literacy association with health behaviors and health care utilization in multiple sclerosis: a cross-sectional study.
Interact J Med Res. 2014 Feb 10;3(1):e3.
Cutter G, Kappos L.
Clinical trials in multiple sclerosis.
Handb Clin Neurol. 2014;122:445-53.